清滋饮对阴虚血瘀证2型糖尿病患者视黄醇结合蛋白、胱抑素C影响的观察
发布时间：2018-09-07 10:48
【摘要】：目的:观察清滋饮对2型糖尿病阴虚血瘀证患者的RBP、CysC的影响及临床疗效与安全性。方法:本研究在随机对照原则指导下,将符合此次研究标准的60例患者,随机分为试验组和对照组。其中前者在西医常规基础治疗之上加上清滋饮内服,后者仅用西医常规基础治疗,两组的治疗疗程相同,均为12周。通过对两组治疗前后血清视黄醇结合蛋白(RBP)、胱抑素 C(CysC)及其他实验室指标(如 BMI、HbAlc、FBG、PBG、TC、TG、LDL-C、HDL-C、Lp(a)、Apo-A、Apo-B、Scr、eGFR等)的变化进行比较,观察其对血清视黄醇结合蛋白、CysC的影响及临床疗效与安全性。结果:治疗后,两组临床症状总评分及血糖等相关实验室指标较未治疗前均有改善(P0.05),且试验组优于对照组。试验组临床症状改善总体有效率为93%,对照组为73%。治疗后两组血脂谱较治疗前均有优化(P0.05),在改善TC、TG、LDL-C方面,试验组优于对照组。治疗后两组Apo-B较治疗前均有下降(P0.05),且试验组下降幅度优于对照组。治疗后CysC、RBP试验组较治疗前均有下降(P0.05),对照组较治疗前无明显统计学差异(P0.05)。治疗后Scr、eGFR试验组较治疗前均有改善(P0.05),对照组较治疗前无明显统计学差异(P0.05)。治疗前后两组肝肾功能比较无明显差异,两组治疗前后均无明显不良反应。结论:清滋饮治疗阴虚血瘀证2型糖尿病患者疗效确切,能降低其证候积分、血糖,调节血脂,降低Apo-B,可降低血清CysC、RBP,改善Scr、eGFR,且无明显不良反应,安全可靠。
[Abstract]:Objective: to observe the effect of Qingzi decoction on RBP,CysC and its clinical efficacy and safety in type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. Methods: under the guidance of randomized control principle, 60 patients who met the criteria of this study were randomly divided into trial group and control group. The former plus Qingzi Yin on the basis of routine western medicine treatment, the latter was only treated with routine western medicine, the two groups were treated for the same course of treatment, both for 12 weeks. By comparing the changes of serum retinol binding protein (RBP), cystatin C (CysC), and other laboratory indexes (such as BMI,HbAlc,FBG,PBG,TC,TG,LDL-C,HDL-C,Lp (a) Apo-An Apo-Bnus ScreGFR, etc.) before and after treatment, the effects, clinical efficacy and safety of serum retinol binding protein (retinol binding protein), CysC, were observed. Results: after treatment, the clinical symptom score and blood sugar were improved in both groups (P0.05), and the experimental group was superior to the control group. The overall effective rate of clinical symptom improvement was 93 in the trial group and 73 in the control group. The blood lipid spectrum of the two groups was optimized after treatment (P0.05), and the experimental group was superior to the control group in improving TC,TG,LDL-C. After treatment, the Apo-B of the two groups was lower than that of the control group (P0.05), and the decrease of Apo-B in the experimental group was better than that in the control group. After treatment, the CysC,RBP test group were lower than before treatment (P0.05), the control group had no statistical difference compared with before treatment (P0.05). After treatment, Scr,eGFR test group were improved compared with before treatment (P0.05), the control group had no significant difference compared with before treatment (P0.05). There was no significant difference in liver and kidney function between the two groups before and after treatment. Conclusion: Qingzi decoction is effective in treating type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. It can reduce syndromes score, blood sugar, regulate blood lipid, and reduce serum CysC,RBP, to improve Scr,eGFR,. There is no obvious adverse reaction and it is safe and reliable.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
本文编号：2228047
[Abstract]:Objective: to observe the effect of Qingzi decoction on RBP,CysC and its clinical efficacy and safety in type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. Methods: under the guidance of randomized control principle, 60 patients who met the criteria of this study were randomly divided into trial group and control group. The former plus Qingzi Yin on the basis of routine western medicine treatment, the latter was only treated with routine western medicine, the two groups were treated for the same course of treatment, both for 12 weeks. By comparing the changes of serum retinol binding protein (RBP), cystatin C (CysC), and other laboratory indexes (such as BMI,HbAlc,FBG,PBG,TC,TG,LDL-C,HDL-C,Lp (a) Apo-An Apo-Bnus ScreGFR, etc.) before and after treatment, the effects, clinical efficacy and safety of serum retinol binding protein (retinol binding protein), CysC, were observed. Results: after treatment, the clinical symptom score and blood sugar were improved in both groups (P0.05), and the experimental group was superior to the control group. The overall effective rate of clinical symptom improvement was 93 in the trial group and 73 in the control group. The blood lipid spectrum of the two groups was optimized after treatment (P0.05), and the experimental group was superior to the control group in improving TC,TG,LDL-C. After treatment, the Apo-B of the two groups was lower than that of the control group (P0.05), and the decrease of Apo-B in the experimental group was better than that in the control group. After treatment, the CysC,RBP test group were lower than before treatment (P0.05), the control group had no statistical difference compared with before treatment (P0.05). After treatment, Scr,eGFR test group were improved compared with before treatment (P0.05), the control group had no significant difference compared with before treatment (P0.05). There was no significant difference in liver and kidney function between the two groups before and after treatment. Conclusion: Qingzi decoction is effective in treating type 2 diabetes mellitus with yin deficiency and blood stasis syndrome. It can reduce syndromes score, blood sugar, regulate blood lipid, and reduce serum CysC,RBP, to improve Scr,eGFR,. There is no obvious adverse reaction and it is safe and reliable.
【学位授予单位】：南京中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
【参考文献】
相关期刊论文 前10条
1 张怀民;傅秀慧;郑海洲;;中药活性成分治疗2型糖尿病及其并发症作用机制的研究进展[J];中国药房;2016年22期
2 王小官;曾勇;;玉液止渴丸治疗消渴病(气阴两虚证)的临床研究[J];湖北中医杂志;2015年12期
3 高静;段畅;李丽娟;;2型糖尿病发病机制的研究进展[J];医学综述;2015年21期
4 付广真;张曼;;2型糖尿病伴背景性及增殖性视网膜病变的血脂六项分析[J];中国卫生检验杂志;2015年07期
5 晏斌;王洪彬;喇孝瑾;李继安;;中药防治2型糖尿病的临床用药分析[J];中国民族民间医药;2014年13期
6 周慎;戴芳芳;;连苏饮加减治疗糖尿病胃轻瘫医案三则[J];实用中医内科杂志;2014年02期
7 张高健;邱蔚;;2型糖尿病合并冠心病患者血清内脂素和视黄醇结合蛋白4的临床意义[J];心脑血管病防治;2013年03期
8 庞博;赵进喜;王世东;祝勇;李景;;祝谌予诊疗糖尿病学术思想与临证经验[J];世界中医药;2013年02期
9 王艳梅;徐远;;徐远教授“达肝法”在消渴病治疗中的应用[J];世界中西医结合杂志;2012年08期
10 崔鹏;李继安;;中药有效成分改善2型糖尿病胰岛素抵抗的研究进展[J];中国煤炭工业医学杂志;2012年05期
，本文编号：2228047
本文链接：https://www.wllwen.com/zhongyixuelunwen/2228047.html
最近更新
教材专著
